Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$74.27MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven L. Basta
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 371
- Beta
- 0.50
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -5.17
Financials
Revenue
$74.27M+10790.6%Net Income
$-17.58MEBITDA
$-2.37MFree Cash Flow
$-1.97MEPS (diluted)
$-0.21Shares Outstanding (diluted)
83.75M+1470.9%Operating Expenses
$63.14MCash & Debt
$182.48MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $175.11M | $-221.25M | $-3.03 |
| 2024 | $55.25M | $-334.33M | $-5.29 |
| 2023 | $682.0K | $-201.59M | $-3.93 |
| 2022 | $0.00 | $-197.72M | $-5.70 |
| 2021 | $0.00 | $-143.88M | $-4.00 |
| 2020 | $0.00 | $-129.07M | $-4.01 |
| 2019 | $0.00 | $-209.74M | $-8.48 |
| 2018 | $0.00 | $-1.29M | $-0.15 |
Valuation
PHAThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+41.18%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Positive
…cacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis FLORHAM PARK, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee.
View source ↗ - Newsglobenewswire.com·9d ago·Positive
…ch proton pump inhibitors (PPIs) are not currently approved in the U.S. FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases, today announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA® (vonopra…
View source ↗ - Newsbusinesswire.com·21d ago·Negative
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $PHAT--PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $0.07 per share
Typical surprise -2.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.21 vs $-0.18miss
- Thu, Apr 30$-0.37 vs $-0.27miss
- Thu, Feb 26$-0.29 vs $-0.32beat
- Thu, Oct 30$-0.41 vs $-0.40miss
- Thu, Aug 7$-0.79 vs $-0.76miss
- Thu, May 1$-1.07 vs $-1.06miss
Estimates and results for PHAT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PHAT officers and directors.
- Bought
- $261k
- Sold
- $265k
9 trades
7 trades
- Breedlove Robert Charlessold
- Breedlove Robert Charlessold
- Breedlove Robert Charlessold
- Topper James Nbought
- Topper James Nbought
- Topper James Nbought
- Topper James Nbought
- Topper James Nbought
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PHAT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.